17-61784279-T-A
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM1BP4_Moderate
The ENST00000259008.7(BRIP1):c.1619A>T(p.Gln540Leu) variant causes a missense change. The variant allele was found at a frequency of 0.0000174 in 1,612,486 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. Q540Q) has been classified as Likely benign.
Frequency
Consequence
ENST00000259008.7 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BRIP1 | NM_032043.3 | c.1619A>T | p.Gln540Leu | missense_variant | 11/20 | ENST00000259008.7 | NP_114432.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRIP1 | ENST00000259008.7 | c.1619A>T | p.Gln540Leu | missense_variant | 11/20 | 1 | NM_032043.3 | ENSP00000259008 | P2 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152226Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000358 AC: 9AN: 251070Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135688
GnomAD4 exome AF: 0.0000164 AC: 24AN: 1460260Hom.: 0 Cov.: 31 AF XY: 0.0000110 AC XY: 8AN XY: 726470
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152226Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74378
ClinVar
Submissions by phenotype
Familial cancer of breast Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 12, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Oct 26, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Mar 01, 2023 | This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk. - |
Hereditary cancer-predisposing syndrome Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 14, 2022 | The p.Q540L variant (also known as c.1619A>T), located in coding exon 10 of the BRIP1 gene, results from an A to T substitution at nucleotide position 1619. The glutamine at codon 540 is replaced by leucine, an amino acid with dissimilar properties. This alteration has been reported in 1/21 BRCA1/2-negative individuals with a personal and family history of breast cancer; however, it was not found in seven of the proband's relatives, including three relatives with breast cancer (Rutter JL et al. Hum. Mutat. 2003 Aug;22:121-8). This alteration has also been reported in a cohort of 48143 individuals diagnosed with invasive breast cancer before the age of 55 years and was not observed in 43608 control subjects (Easton DF et al. J. Med. Genet. 2016 May;53:298-309). In another study, this alteration was observed in 0/706 cases with ovarian cancer, 0/6,341 cases with breast cancer and in 1/36,687 controls (Weber-Lassalle N et al. Breast Cancer Res. 2018 Jan;20:7). In one study, this alteration was detected in 1/2160 early-onset breast cancer cases and 1/1,199 ovarian cancer cases; the patient with ovarian cancer also had a pathogenic alteration in BRCA1 or BRCA2 (Moyer CL et al. Cancer Res. 2020 Feb;80:857-867). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Jul 12, 2016 | - - |
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | May 15, 2021 | - - |
Familial cancer of breast;C1836860:Fanconi anemia complementation group J Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 16, 2024 | This sequence change replaces glutamine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 540 of the BRIP1 protein (p.Gln540Leu). This variant is present in population databases (rs4988349, gnomAD 0.07%). This missense change has been observed in individual(s) with breast cancer (PMID: 12872252, 31822495). ClinVar contains an entry for this variant (Variation ID: 142473). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRIP1 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 24, 2017 | Variant summary: The BRIP1 c.1619A>T (p.Gln540Leu) variant involves the alteration of a conserved nucleotide and 2/4 in silico tools predict a benign outcome for this variant (SNPsandGO not captured due to low reliability index). However, these predictions have yet to be functionally assessed. This variant was found in 7/349872 control chromosomes (gnomAD), predominantly observed in the Ashkenazi Jewish subpopulation at a frequency of 0.000712 (7/9838). This frequency is about 11 times the estimated maximal expected allele frequency of a pathogenic BRIP1 variant (0.0000625), suggesting this is likely a benign polymorphism found primarily in those of Ashkenazi Jewish origin. A publication, Rutter_2003, indicates the variant was found in a Breast Cancer family, which three affected family members did not carry the variant of interest showing lack of cosegregation. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as uncertain significance. Taken together, this variant is classified as a "Variant of Uncertain Significance - Possibly Benign." - |
Ovarian neoplasm;C1836860:Fanconi anemia complementation group J Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Oct 04, 2017 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Nov 19, 2023 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26659599, 31822495, 12872252, 26921362, 19584272, 27527004, 29368626, 36845387) - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at